Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

Status:
Recruiting
Trial end date:
2023-07-21
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mosunetuzumab in participants with systemic lupus erythematosus (SLE).
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche